A Phase 3 Randomized Controlled Trial of a COVID-19 Recombinant Vaccine S-268019-b Versus ChAdOx1 NCoV-19 in Japanese Adults

Overview

Journal Sci Rep

Specialty Science

Date 2024 Apr 29

PMID 38684712

Authors

Satoshi Iwata

Andrew J Pollard

Yukio Tada

Shinya Omoto

Risa Y Shibata

Kenji Igarashi

Takahiro Hasegawa

Mari Ariyasu

Takuhiro Sonoyama

Affiliations

Soon will be listed here.

Abstract

We assessed S-268019-b, a recombinant spike protein vaccine with a squalene-based adjuvant, for superiority in its immunogenicity over ChAdOx1 nCoV-19 vaccine among adults in Japan. In this multicenter, randomized, observer-blinded, phase 3 study, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-naïve participants (aged ≥ 18 years, without prior infection or vaccination against SARS-CoV-2) were randomized (1:1) to receive either S-268019-b or ChAdOx1 nCoV-19 as two intramuscular injections given 28 days apart. Participants who provided consent for a booster administration received S-268019-b at Day 211. The primary endpoint was SARS-CoV-2 neutralizing antibody (NAb) titer on Day 57; the key secondary endpoint was the seroconversion rate for SARS-CoV-2 NAb titer on Day 57. Other endpoints included anti-SARS-CoV-2 S-protein immunoglobulin (Ig)G antibody titer and safety. The demographic and baseline characteristics were generally comparable between S-268019-b (n = 611) and ChAdOx1 nCoV-19 (n = 610) groups. S-268019-b showed superior immunogenicity over ChAdOx1 nCoV-19, based on their geometric mean titers (GMTs) and GMT ratios of SARS-CoV-2 NAb on Day 57 by cytopathic effect assay (GMT [95% confidence interval {CI}] 19.92 [18.68, 21.23] versus 3.63 [3.41, 3.87]; GMT ratio [95% CI] 5.48 [5.01, 6.00], respectively; two-sided p-values < 0.0001). Additionally, NAb measured using a cell viability assay also showed similar results (GMT [95% CI] 183.25 [168.04, 199.84] versus 24.79 [22.77, 27.00]; GMT ratio [95% CI] 7.39 [6.55, 8.35] for S-268019-b versus ChAdOx1 nCoV-19, respectively; p < 0.0001). The GMT of anti-SARS-CoV-2 S-protein IgG antibody was 370.05 for S-268019-b versus 77.92 for ChAdOx1 nCoV-19 on Day 57 (GMT ratio [95% CI] 4.75 [4.34, 5.20]). Notably, immune responses were durable through the end of the study. S-268019-b elicited T-helper 1 skewed T-cell response, comparable to that of ChAdOx1 nCoV-19. After the first dose, the incidence of solicited systemic treatment-related adverse events (TRAEs) was higher in the ChAdOx1 nCoV-19 group, but after the second dose, the incidence was higher in the S-268019-b group. Headache, fatigue, and myalgia were the most commonly reported solicited systemic TRAEs, while pain at the injection site was the most frequently reported solicited local TRAE following both doses in both groups. No serious treatment-related adverse serious TRAEs events were reported in the two groups. S-268019-b was more immunogenic than ChAdOx1 nCoV-19 vaccine and was well tolerated (jRCT2051210151).

References

Feng S, Phillips D, White T, Sayal H, Aley P, Bibi S . Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(11):2032-2040. PMC: 8604724. DOI: 10.1038/s41591-021-01540-1. View

Gobeil P, Pillet S, Boulay I, Charland N, Lorin A, Cheng M . Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19. Nat Commun. 2022; 13(1):6905. PMC: 9653456. DOI: 10.1038/s41467-022-34728-1. View

Montplaisir J, Petit D, Quinn M, Ouakki M, Deceuninck G, Desautels A . Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One. 2014; 9(9):e108489. PMC: 4180737. DOI: 10.1371/journal.pone.0108489. View

Asano M, Okada H, Itoh Y, Hirata H, Ishikawa K, Yoshida E . Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. Int J Infect Dis. 2021; 114:165-174. PMC: 8531242. DOI: 10.1016/j.ijid.2021.10.030. View

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

Muik A, Lui B, Wallisch A, Bacher M, Muhl J, Reinholz J . Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022; 375(6581):678-680. PMC: 9836206. DOI: 10.1126/science.abn7591. View

Kulkarni P, Padmapriyadarsini C, Vekemans J, Bavdekar A, Gupta M, Kulkarni P . A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine. 2021; 42:101218. PMC: 8629682. DOI: 10.1016/j.eclinm.2021.101218. View

Choe P, Kang C, Suh H, Jung J, Song K, Bang J . Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection. Emerg Infect Dis. 2020; 27(1). PMC: 7774548. DOI: 10.3201/eid2701.203515. View

Hashimoto M, Nagata N, Homma T, Maeda H, Dohi K, Seki N . Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys. Vaccine. 2022; 40(31):4231-4241. PMC: 9167832. DOI: 10.1016/j.vaccine.2022.05.081. View

10.

Ewer K, Barrett J, Belij-Rammerstorfer S, Sharpe H, Makinson R, Morter R . T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2020; 27(2):270-278. DOI: 10.1038/s41591-020-01194-5. View

11.

Pavot V, Berry C, Kishko M, Anosova N, Huang D, Tibbitts T . Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates. Nat Commun. 2022; 13(1):1699. PMC: 8971430. DOI: 10.1038/s41467-022-29219-2. View

12.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

13.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

14.

Lazarus R, Querton B, Ramljak I, Dewasthaly S, Jaramillo J, Dubischar K . Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial. Lancet Infect Dis. 2022; 22(12):1716-1727. PMC: 9444237. DOI: 10.1016/S1473-3099(22)00502-3. View

15.

Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

16.

Sonoyama T, Kamitani A, Shibata R, Seki N, Omoto S, Igarashi K . Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan. Vaccine X. 2023; 15:100390. PMC: 10562875. DOI: 10.1016/j.jvacx.2023.100390. View

17.

Korosec C, Farhang-Sardroodi S, Dick D, Gholami S, Ghaemi M, Moyles I . Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex. Sci Rep. 2022; 12(1):21232. PMC: 9732004. DOI: 10.1038/s41598-022-25134-0. View

18.

Shinkai M, Sonoyama T, Kamitani A, Yokokawa Shibata R, Seki N, Omoto S . Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study. Vaccine. 2022; 40(32):4328-4333. PMC: 9212435. DOI: 10.1016/j.vaccine.2022.06.032. View

19.

Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S . Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings. Vaccine. 2022; 40(27):3721-3726. PMC: 9122779. DOI: 10.1016/j.vaccine.2022.04.054. View

20.

Krammer F . A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat Med. 2021; 27(7):1147-1148. DOI: 10.1038/s41591-021-01432-4. View